PROFILPELAJAR.COM

Sifalimumab
	Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interferon α
Clinical data
ATC code	none;
Identifiers
CAS Number	1006877-41-3 ;
ChemSpider	none;
UNII	XOY1YA7RMC;
KEGG	D09668;
Chemical and physical data
Formula	C6518H10008N1724O2032S38
Molar mass	146252.08 g·mol−1
	(what is this?) (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.^[1] It targets interferon a.^[2]

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.^[3]^[4]^[5]

References

^ Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B (January 2017). "Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus". Immunotherapy. 9 (1): 57–70. doi:10.2217/imt-2016-0090. PMID 28000522.
^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
^ "Sifalimumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 July 2017.
^ "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.